Introduction to Palnat 125 mg
Palbociclib 125 mg is an essential drug in the fight against breast cancer. It specifically targets hormone receptor-positive, HER2-negative breast cancer. Palnat helps by blocking cancer cells from dividing and multiplying, slowing or stopping the disease’s progression. Palnat 125mg Capsule helps by preventing cancer cells from dividing and spreading, slowing down the disease.
As a generic version of Ibrance, Palnat offers the same benefits at a lower cost, making it more accessible to patients who need long-term treatment. This availability offers a vital option for many, ensuring that effective treatment is accessible to more people. Palnat is crucial in treating a common and tough form of breast cancer, giving patients an affordable and targeted therapy option.
Definition and Role of Palbociclib
Palbociclib is the main ingredient in Palnat Capsules. It blocks certain enzymes called CDK4 and CDK6. These enzymes are essential for cancer cell growth. By blocking them, Palbociclib slows down the cancer cells’ growth.
How Palbociclib Works
Palbociclib inhibits the activity of CDK4 and CDK6, proteins that help cells divide. In cancer cells, these proteins can become hyperactive, leading to uncontrolled growth. By inhibiting CDK4 and CDK6, Palnat prevents cancer cells from dividing and leads them to die. This method effectively manages hormone receptor-positive breast cancer.
Palbociclib specifically treats hormone receptor-positive, HER2-negative advanced breast cancer. This cancer type has tumors that respond to hormones like estrogen but do not produce excess HER2 protein. Palnat helps control the growth of these hormone-sensitive tumors, improving patient outcomes and extending disease control.
Palbociclib FDA Approval
On February 31, 2017, the FDA granted regular approval for palbociclib, the active component in Palnat 125mg. It is used to treat advanced or metastatic breast cancer that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). It is prescribed with an aromatase inhibitor or fulvestrant.
The FDA approved palbociclib based on the PALOMA-1 clinical trial, which showed that combining palbociclib with letrozole improved progression-free survival in postmenopausal women compared to letrozole alone. This led to fast-track approval under the Breakthrough Therapy designation due to its significant benefits for patients.
Dosage and Administration
Standard Dosage for Palnat 125mg Capsules
- Take 125 mg of Palnat (Palbociclib 125mg) Capsule once daily for 21 days in a 28-day cycle
- Usually taken with other hormone therapies
Proper Administration Instructions
- Take at the same time each day
- Swallow whole with a glass of water
- Do not crush or chew
- Can be taken with or without food
Adjustments Based on Patient Needs
- Dose Adjustments: Adjustments may be needed based on liver function or side effects
- Hepatic Impairment: May require a reduced dose for liver issues
Guidelines for Missed Dose or Overdose
- Missed Dose: Take as soon as remembered, or skip if close to the next dose
- Overdose: Seek immediate medical attention and contact a healthcare provider
Always follow your doctor’s instructions for proper usage and dosage adjustments.
Storage Instruction for Palnat 125 mg
- Keep Palnat at room temperature, between 20C to 25C (68F to 77F)
- Store the medication in a dry place, away from moisture and humidity
- Do not store in the bathroom
- Keep the medication in its original container with the lid tightly closed
- Store Palnat out of the reach of children and pets
- Check the expiry date and do not use past this date
Palbociclib Side Effects
Side effects are unwanted symptoms that can occur with medications. While most medicines can cause side effects, not everyone will experience them.
Common Side Effects
- Tiredness
- Hair loss
- Dry skin, rash
- Infections
- Low blood cell counts
- Decreased appetite
- Nausea, vomiting
- Diarrhea
- Swelling of the lips and mouth
- Changes in taste
- Nose bleed
- Dry eye, blurred vision, increased tearing
Serious Side Effects
- Blood disorder (fever, chills, shortness of breath, weakness, bleeding, or bruising)
- Lung inflammation (chest pain, dry cough, or difficulty breathing)
Precautions While Taking Palnat 125mg
- Avoid Pregnancy: Palbociclib can harm an unborn baby. Use reliable birth control during treatment and for at least three weeks after the last dose
- Infection Risk: Palbociclib may lower white blood cell count, increasing infection risk
- Liver Function Monitoring: Regular liver tests are required
- Limit Alcohol Consumption: Alcohol can worsen side effects, especially liver issues
- Avoid Grapefruit: Grapefruit and its juice can increase side effects
Approval
https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance
Palnat vs. Ibrance
Comparative Overview
| Feature | Palnat (Palbociclib 125mg) | Ibrance (Palbociclib 125mg) |
|---|---|---|
| Active Ingredient | Palbociclib | Palbociclib |
| Manufacturer | Natco Pharma | Pfizer |
| FDA Approval | Equivalent to Ibrance, not independently FDA-approved | FDA-approved (2017) |
| Indication | HR+/HER2- Advanced or Metastatic Breast Cancer | HR+/HER2- Advanced or Metastatic Breast Cancer |
| Mechanism of Action | CDK4/6 Inhibitor | CDK4/6 Inhibitor |
| Pricing | $178 (apx) | $17,000 (apx) |
| Availability | May vary by country or region | Widely available globally |
| Combination Therapy | Aromatase Inhibitors or Fulvestrant | Aromatase Inhibitors or Fulvestrant |
| Efficacy | Comparable to Ibrance in clinical usage | Proven efficacy (PALOMA trials) |







Lauren Lewis –
The service was excellent and I am impressed with the lowest prices with fast delivery